C R Chapple

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    Expert Opin Pharmacother 7:2421-34. 2006
  2. ncbi New once-daily formulation for trospium in overactive bladder
    C Chapple
    Royal Hallamshire Hospital, Sheffield, UK
    Int J Clin Pract 64:1535-40. 2010
  3. ncbi Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers
    Christopher Chapple
    Sheffield Teaching Hospitals, Sheffield, UK
    Eur Urol 56:534-41. 2009
  4. ncbi Tamsulosin: an overview
    Christopher Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    World J Urol 19:397-404. 2002
  5. ncbi Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia
    Christopher Chapple
    Sheffield Teaching Hospitals, Sheffield, UK
    Curr Opin Urol 20:43-8. 2010
  6. ncbi Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Department of Urology, Glossop Road, Sheffield, S10 2JF, UK
    Expert Opin Investig Drugs 13:1493-500. 2004
  7. ncbi Comparison of fesoterodine and tolterodine in patients with overactive bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 102:1128-32. 2008
  8. ncbi The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis
    Christopher R Chapple
    Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Urology Research, Sheffield, UK
    Eur Urol 54:543-62. 2008
  9. ncbi The urgency of the problem and the problem of urgency in the overactive bladder
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    BJU Int 95:274-5. 2005
  10. ncbi Management of the failure of a permanently implanted urethral stent-a therapeutic challenge
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 54:665-70. 2008

Detail Information

Publications80

  1. ncbi Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    Expert Opin Pharmacother 7:2421-34. 2006
    ..The favourable efficacy and safety profile of solifenacin, coupled with its dose flexibility, are consistent with solifenacin being a convenient treatment option for patients with OAB...
  2. ncbi New once-daily formulation for trospium in overactive bladder
    C Chapple
    Royal Hallamshire Hospital, Sheffield, UK
    Int J Clin Pract 64:1535-40. 2010
    ..AIMS We examined the relative efficacy and safety of trospium 20 mg bid and 60 mg extended release formulations and position this drug against other antimuscarinic agents...
  3. ncbi Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers
    Christopher Chapple
    Sheffield Teaching Hospitals, Sheffield, UK
    Eur Urol 56:534-41. 2009
    ..Some men receiving alpha-blocker therapy for lower urinary tract symptoms report persistent storage symptoms suggestive of overactive bladder (OAB)...
  4. ncbi Tamsulosin: an overview
    Christopher Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    World J Urol 19:397-404. 2002
    ....
  5. ncbi Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia
    Christopher Chapple
    Sheffield Teaching Hospitals, Sheffield, UK
    Curr Opin Urol 20:43-8. 2010
    ..This review will provide an update on the use of antimuscarinics, in combination with an alpha-blocker, in men with an overactive bladder and summarize the efficacy and safety of these drugs in this patient population...
  6. ncbi Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Department of Urology, Glossop Road, Sheffield, S10 2JF, UK
    Expert Opin Investig Drugs 13:1493-500. 2004
    ..On the basis of such findings, darifenacin would appear to meet the current need for an effective OAB pharmacotherapy that is efficacious, well-tolerated and, more importantly, minimises the risk of safety-related adverse effects...
  7. ncbi Comparison of fesoterodine and tolterodine in patients with overactive bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 102:1128-32. 2008
    ....
  8. ncbi The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis
    Christopher R Chapple
    Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Urology Research, Sheffield, UK
    Eur Urol 54:543-62. 2008
    ..Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder...
  9. ncbi The urgency of the problem and the problem of urgency in the overactive bladder
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    BJU Int 95:274-5. 2005
  10. ncbi Management of the failure of a permanently implanted urethral stent-a therapeutic challenge
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 54:665-70. 2008
    ..To demonstrate the surgical challenges posed and strategies that can be adopted to deal with failed stent insertion after prior urethroplasty or traumatic injury to the urethra...
  11. ncbi Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial
    C Chapple
    Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Hallam University, UK
    Curr Med Res Opin 23:2347-58. 2007
    ..Overactive bladder (OAB) increases in prevalence with advancing age. This study specifically investigated patients >or= 65 years, evaluating the efficacy, tolerability, safety and quality of life (QoL) outcomes from darifenacin treatment...
  12. ncbi Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Drugs R D 3:75-81. 2002
    ..This study further evaluated the selectivity profiles of tolterodine and oxybutynin by comparing the effects on bladder function and visual accommodation in the same individuals...
  13. ncbi Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder
    Christopher Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 52:1204-12. 2007
    ..To determine the efficacy, tolerability, and safety of fesoterodine in subjects with overactive bladder (OAB)...
  14. ncbi Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia
    C R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 35:119-28. 1999
    ..The objective of this article is to discuss the basics of radiofrequency energy, instrumentation, surgical techniques, and to present an update of the clinical results as it applies to the treatment of BPH...
  15. ncbi Contemporary management of urethral trauma and the post-traumatic stricture
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Curr Opin Urol 9:253-60. 1999
    ..The principles of urethral reconstruction in both the anterior and posterior urethra are discussed, with reference to the recent literature on the subject...
  16. ncbi Consensus statement on urethral trauma
    C Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 93:1195-202. 2004
  17. ncbi Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK
    Eur Urol 59:342-52. 2011
    ..Silodosin is a new selective therapy with a high pharmacologic selectivity for the ?(1A)-adrenoreceptor...
  18. ncbi Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none?
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Nat Clin Pract Urol 2:555-64. 2005
    ....
  19. ncbi Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 93:303-10. 2004
    ..e. urgency, incontinence, and frequency, with additional objectives being to assess the safety and tolerability of solifenacin and to compare the efficacy and safety of solifenacin with tolterodine 2 mg twice daily...
  20. ncbi Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study
    C R Chapple
    Royal Hallamshire Hospital, Sheffield, UK, Puigvert Foundation, Barcelona, Spain
    BJU Int 93:71-7. 2004
    ..To evaluate the dose-response relationship and safety/tolerability of solifenacin succinate (YM905) in the treatment of overactive bladder (OAB), and to compare its efficacy and safety/tolerability with tolterodine 2 mg twice daily...
  21. ncbi A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 49:651-8. 2006
    ....
  22. ncbi A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder
    Christopher Chapple
    Urology Research, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 95:993-1001. 2005
    ....
  23. ncbi Solifenacin significantly improves all symptoms of overactive bladder syndrome
    C R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    Int J Clin Pract 60:959-66. 2006
    ..Adverse events were mainly mild-to-moderate in all treatment groups. The results of these phase III trials support the use of solifenacin in the treatment of OAB...
  24. ncbi Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology
    D J Rosario
    Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Neurourol Urodyn 18:223-33; discussion 223-4. 1999
    ..Correlation between symptoms and findings on AUM is good with changes in parameters recorded on AUM relating closely to the improvement in symptoms...
  25. ncbi A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
    C R Chapple
    Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, Urology Research, South Yorkshire, UK
    Eur Urol 48:464-70. 2005
    ..To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome (OAB)...
  26. ncbi Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity
    S C Radley
    Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    J Urol 166:2253-8. 2001
    ..In women who complain of urgency stable conventional cystometrography findings should be interpreted with caution...
  27. ncbi Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    Eur Urol 48:102-9. 2005
    ..To evaluate the effects of darifenacin, an M3 selective receptor antagonist, compared with oxybutynin, on ambulatory urodynamics, salivary flow, heart rate and visual nearpoint in patients with overactive bladder (OAB)...
  28. ncbi Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study
    S C Radley
    Urology Research Department, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Neurourol Urodyn 20:43-52. 2001
    ....
  29. ncbi Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder
    L A Stevens
    Biomedical Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
    Auton Autacoid Pharmacol 26:303-9. 2006
    ..The overactivity is associated with an enhanced sensitivity to carbachol, which is partly explained by an increase in receptor density, but there appears to be no change in receptor/G-protein coupling...
  30. ncbi Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 93:599-604. 2004
    ....
  31. ncbi Buccal mucosal urethroplasty: is it the new gold standard?
    S Bhargava
    Department of Urology, Section of Reconstruction, Urodynamics and Female Urology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, UK
    BJU Int 93:1191-3. 2004
    ..Thus, buccal mucosa is most likely to become the new gold standard for substitution urethroplasty and longer term results with its use are eagerly awaited...
  32. ncbi Potential therapeutic targets for treatment of the overactive bladder
    D J Sellers
    Division of Biomedical Science, School of Science and Mathematics, Sheffield Hallam University, UK
    World J Urol 19:307-11. 2001
    ....
  33. ncbi Transurethral implantation of macroplastique for the treatment of female stress urinary incontinence secondary to urethral sphincter deficiency
    S C Radley
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 39:383-9. 2001
    ..To assess the results of transurethral implantation of Macroplastique in women with stress incontinence secondary to urethral sphincter deficiency using subjective and objective outcome measures...
  34. ncbi Investigation of neurokinin-2 and -3 receptors in the human and pig bladder
    L Templeman
    Department of Biomedical Science, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 92:787-92. 2003
    ..The results also provide evidence that the NK-2 receptor in human and pig are the same, and the latter may be an appropriate species to study tachykinin-induced contractions in human bladder...
  35. ncbi Alpha adrenoceptor antagonists in the year 2000: is there anything new?
    C R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    Curr Opin Urol 11:9-16. 2001
    ..The implications of the ALLHAT study are discussed...
  36. ncbi Medical therapy and quality of life
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 34:10-7; discussion 46. 1998
    ..These documented properties of the alpha 1A-adrenoceptor antagonists make them an ideal choice for the medical treatment of symptomatic BPH...
  37. ncbi Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: design and implementation
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    Eur Urol 39:31-6. 2001
    ..The last patient is anticipated to come out of the initial prospective survey by the end of 2002/beginning of 2003 and the results will hopefully contribute to improved cost-effective management of LUTS suggestive of BPO in the future...
  38. ncbi The acute effect of magnetic stimulation of the pelvic floor on involuntary detrusor activity during natural filling and overactive bladder symptoms
    H D Bradshaw
    Department of Urology, Sheffield Teaching Hospitals, UK
    BJU Int 91:810-3. 2003
    ..To evaluate the effect of magnetic stimulation of the pelvic floor (MSPF) on involuntary detrusor activity observed during natural filling, and on the overactive bladder symptom complex...
  39. ncbi The role of alpha1D-adrenoceptors in prostatic contraction examined using protection studies
    R Chess-Williams
    Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield, UK
    Auton Autacoid Pharmacol 22:291-6. 2002
    ..4 These results suggest that in human prostate functional alpha1D-adrenoceptors do not contribute to noradrenaline-induced contractile responses...
  40. ncbi Tissue-engineered buccal mucosa for substitution urethroplasty
    S Bhargava
    Department of Urology, Section of Reconstruction, Urodynamics and Female Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, South Yorkshire, UK
    BJU Int 93:807-11. 2004
    ..CONCLUSIONS: We report the successful culture of full-thickness TEBM for substitution urethroplasty, which is robust and suitable for clinical use...
  41. ncbi Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004)
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    Eur Urol 49:879-86. 2006
    ..This is the first clinical study to be reported in full for the use of a potassium channel opener in OAB...
  42. ncbi Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction
    Laurie A Stevens
    Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom
    Eur Urol 52:531-8. 2007
    ..This study examines whether M(2) receptors contribute to direct contraction of the detrusor in human neurogenic and idiopathic overactive bladders...
  43. ncbi Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg
    Christopher R Chapple
    Urology Research Office, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 52:1195-203. 2007
    ..To compare OAB symptom outcomes following initial randomised treatment with solifenacin 5 mg or tolterodine ER 4 mg at the 4-week clinic-visit and again at 12 weeks for patients choosing to remain on this treatment dose from 4 weeks...
  44. ncbi Medical management of lower urinary tract symptoms in men: current treatment and future approaches
    Anand K Patel
    Royal Hallamshire Hospital, Sheffield, UK
    Nat Clin Pract Urol 5:211-9. 2008
    ....
  45. ncbi Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL)
    Martin C Michel
    Department of Pharmacology and Pharmacotherapy, University of Amsterdam, AMC, Amsterdam, The Netherlands
    Eur Urol 49:501-8; discussion 508-9. 2006
    ..The cardiovascular (CV) effects of tamsulosin oral controlled absorption system (OCAS) 0.4 mg were compared with those of alfuzosin prolonged release (XL) 10 mg...
  46. ncbi Improved quality of life in patients with overactive bladder symptoms treated with solifenacin
    Con J Kelleher
    Guy s and St Thomas Hospital, London, UK
    BJU Int 95:81-5. 2005
    ..To assess the effect of solifenacin succinate treatment on quality of life (QoL) measured in clinical trials in patients with overactive bladder (OAB)...
  47. ncbi Stress incontinence injection therapy: what is best for our patients?
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, Glossop Road, Sheffield, South Yorkshire S10 2JF, UK
    Eur Urol 48:552-65. 2005
    ..This review aims to determine which women should potentially benefit from, and be considered as candidates for, injection therapy and to elucidate what we are trying to achieve...
  48. ncbi The role of M2 muscarinic receptor subtypes mediating contraction of the circular and longitudinal smooth muscle of the pig proximal urethra
    Tomonori Yamanishi
    Department of Biomedical Science, University of Sheffield, United Kingdom
    J Urol 168:308-14. 2002
    ..After cAMP elevation a contribution to contraction of M2 receptors appeared to be demonstrated in the 2 tissues but the involvement of M2 receptors appeared greater in circular muscle...
  49. ncbi Definition of normality of pressure-flow parameters based on observations in asymptomatic men
    Derek J Rosario
    Academic Urology Unit, University of Sheffield, Sheffield, UK
    Neurourol Urodyn 27:388-94. 2008
    ....
  50. ncbi Towards a better understanding of involuntary detrusor activity
    Helen D Bradshaw
    Department of Urology Research, Sheffield Teaching Hospitals, UK
    BJU Int 95:799-803. 2005
    ..Finally, authors from Switzerland describe their use of sacral magnetic stimulation in non-inflammatory chronic pelvic pain syndrome...
  51. ncbi Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
    Christopher R Chapple
    Department of Urology, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 94:738-44. 2004
    ..Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH/LUTS...
  52. ncbi The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects
    Christopher R Chapple
    Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    BJU Int 95:335-40. 2005
    ..To review the concept of urinary urgency and its practical measurement in clinical trials, and advance the hypothesis that while urge is experienced by normal people, urgency is always pathological...
  53. ncbi Tissue-engineered buccal mucosa urethroplasty-clinical outcomes
    Saurabh Bhargava
    Section of Reconstruction, Urodynamics and Female Urology, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 53:1263-9. 2008
    ..Previously we described the development of autologous tissue-engineered buccal mucosa (TEBM). Here we report clinical outcomes of the first human series of its use in substitution urethroplasty...
  54. ncbi Recent advances in basic science for overactive bladder
    Vivek Kumar
    Department of Urology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
    Curr Opin Urol 15:222-6. 2005
    ....
  55. ncbi Recent developments in the management of detrusor overactivity
    Vivek Kumar
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Curr Opin Urol 13:285-91. 2003
    ..Present treatments for overactive bladders have significant non-compliance rates. Hopefully, future research will lead to drugs with greater therapeutic benefits and better tolerance...
  56. ncbi Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation
    Vivek Kumar
    Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    J Urol 178:1533-6. 2007
    ..We established the level of adenosine triphosphate release by the urothelium in patients with painful bladder syndrome and compared it with that from the normal human bladder...
  57. ncbi Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle
    Donna J Sellers
    Biomedical Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
    Eur Urol 49:510-8. 2006
    ..The present study investigates neurokinin receptor-mediated contractility of detrusor muscle in the idiopathic overactive and neurogenic overactive bladder and investigates the neurokinin receptor subtypes involved...
  58. ncbi Muscarinic receptor subtypes and management of the overactive bladder
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, England, UK
    Urology 60:82-8; discussion 88-9. 2002
    ....
  59. ncbi Urodynamics in the management of female stress incontinence--which test and when?
    Anand K Patel
    Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK
    Curr Opin Urol 18:359-64. 2008
    ....
  60. ncbi Overview consensus statement
    David R Staskin
    Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
    Urology 60:1-6. 2002
  61. ncbi Surgical techniques in substitution urethroplasty using buccal mucosa for the treatment of anterior urethral strictures
    Jacob M Patterson
    Section of Female and Reconstructive Urology, Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Eur Urol 53:1162-71. 2008
    ..Since the resurgence in the use of buccal mucosa (BM) in substitution urethroplasty in the late 1980s and early 1990s, there has been controversy as to which surgical technique is the most appropriate for its application...
  62. ncbi Clinical study of benign prostatic disease, current concepts and future prospects: randomized controlled trials versus real life practice
    Christopher R Chapple
    Curr Opin Urol 13:1-5. 2003
  63. ncbi Identification of beta-adrenoceptor subtypes in lower urinary tract of the female pig
    Tomonori Yamanishi
    Department of Biomedical Science, University of Sheffield, Royal Hallamshire Hospital, United Kingdom
    J Urol 168:2706-10. 2002
    ..We investigated the presence and functional role of beta-adrenoceptor subtypes in the bladder base and proximal urethra of the female pig...
  64. ncbi (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Illinois 60064, USA
    J Pharmacol Exp Ther 303:379-86. 2002
    ..The pharmacological profile of A-278637 represents an attractive basis for further investigations of selective K(ATP) channel openers for the treatment of overactive bladder via myogenic etiology...
  65. ncbi Are slings now the gold standard treatment for the management of female urinary stress incontinence and if so which technique?
    Bart L H Bemelmans
    Department of Urology, University Medical Center, Nijmegen, The Netherlands
    Curr Opin Urol 13:301-7. 2003
    ..These reflections should include (patho)physiology, historical background, and alternative techniques and materials...
  66. ncbi A pragmatic approach to the primary care management of men with lower urinary tract symptoms
    Christopher R Chapple
    Int J Clin Pract 61:1423-5. 2007
  67. ncbi The functional role of beta-adrenoceptor subtypes in mediating relaxation of pig urethral smooth muscle
    Tomonori Yamanishi
    Department of Urology, Dokkyo University, Mibu, Tochigi, Japan
    J Urol 170:2508-11. 2003
    ..The predominant beta-adrenoceptor subtype present in the bladder and urethra is beta3-adrenoceptors. We investigated the role of beta-adrenoceptors in mediating relaxation of the in vitro female pig urethra...
  68. ncbi An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence
    Christopher R Chapple
    Sheffield Teaching Hospitals NHS Trust, Urology Research, Royal Hallamshire Hospital, South Yorkshire, UK
    Eur Urol 48:488-94. 2005
    ..This open, 12-month study was performed to evaluate the safety and efficacy of this system in women with SUI...
  69. ncbi Female urethral diverticula
    Anand K Patel
    Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
    Curr Opin Urol 16:248-54. 2006
    ..The greatest single improvement, however, in management would come from more widespread clinical awareness of the condition and its presentation...
  70. ncbi Botulinum toxin in urinary incontinence
    Jacob M Patterson
    Department of Urology, Section of Female Urology, Urodynamics and Reconstructive Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK
    Curr Opin Urol 16:255-60. 2006
    ..This review discusses recently published literature related to the role of botulinum toxin in treating incontinence, including the place for repeated treatment, the differing types of toxin available and the side effects of its use...
  71. ncbi Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy
    Christopher R Chapple
    Urology Research Department, J Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    Int Urogynecol J Pelvic Floor Dysfunct 18:199-205. 2007
    ..In conclusion, quality-of-life improvements after urethral injection appear significant and comparable to those obtained with surgery. Further study of patients' own perceptions, pre- and posttreatment, would be valuable...
  72. ncbi A critical review of diagnostic criteria for evaluating patients with symptomatic stress urinary incontinence
    Christopher R Chapple
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    BJU Int 95:327-34. 2005
    ..They found that it is appropriate to recommend tamsulosin for such use in this condition...
  73. ncbi Developments in pharmacological therapy for the overactive bladder
    Christopher R Chapple
    Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Hallam University, Sheffield, UK
    BJU Int 98:78-87; discussion 88-9. 2006
  74. ncbi Benign prostatic hyperplasia: treatment in primary care
    Anand K Patel
    Urology Research, J Floor, Royal Hallamshire Hospital, Sheffield S10 2JF
    BMJ 333:535-9. 2006
  75. ncbi Current and future trends in the management of overactive bladder
    Adrian Wagg
    University College Hospital, 25 Grafton Way, NW1 OPE, London, UK
    Int Urogynecol J Pelvic Floor Dysfunct 18:81-94. 2007
    ..The current state and future developments in pharmacological therapy are also outlined...
  76. ncbi Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails
    Derek J Rosario
    Academic Urology Unit, University of Sheffield, Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    J Urol 177:1047-51; discussion 1051. 2007
    ....
  77. ncbi A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome
    Sylvia M Bates
    Department of Genito Urinary Medicine, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 99:355-9. 2007
    ..To assess the validity of our observational experience that a short course of oral prednisolone therapy might be of value in the management of symptoms of chronic pelvic pain syndrome (CPPS) in men...
  78. ncbi The role of the urothelium in mediating bladder responses to isoprenaline
    Shigetaka Murakami
    Biomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield, UK
    BJU Int 99:669-73. 2007
    ....
  79. ncbi A rational approach to benign prostatic hyperplasia evaluation: recent advances
    Saurabh Bhargava
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    Curr Opin Urol 14:1-6. 2004
    ..Other methods should be reserved for more complex situations. Attempts should be made at identifying those patients in whom the disease process is likely to progress...
  80. ncbi The role of M2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M3 inactivation
    Tomonori Yamanishi
    Department of Urology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, United Kingdom
    J Urol 167:397-401. 2002
    ..Involvement of M2 receptors was only noted after selective M3 inactivation and cyclic adenosine monophosphate elevation...